天美传媒

Dr. Walter has spent his 28-year academic career at a primarily undergraduate campus that has just recently been designated an 鈥淓merging Research Institution.鈥� He has served in the Department of Biology (9 years) and then moved to the Department of Chemistry & Biochemistry to assist in development of a Biochemistry undergraduate program. Dr. Walter developed partnership grant proposals aimed towards providing scholarships for student groups that are underrepresented in the sciences (URM). In Fall 2013, he was awarded a Bridges to Biomedicine (B2B) grant wherein Texas State University is partnering with two Alamo Community College campuses to establish a program focused on increasing success of URM students in the biomedical sciences upon transfer to the baccalaureate institution. The B2B program addresses the most important obstacles to upper-division degree completion experienced by students showing an early commitment to a biomedical career. Additionally, Dr. Walter serves as Co-PI for the South Texas Doctoral Bridge Program (STDBP).  The STDBP is aimed at student matriculation from the MS degree into highly competitive doctoral programs. The STDBP is established between the Univ. of Texas Health Science Center at San Antonio (UTHSCSA, medical school) and Texas State University. The STDBP is designed to provide a combination of mentoring and student development activities as well as enhance didactics and research training during a thesis-based M.S. degree in Biochemistry.

Shawn Ryan is the Director of the Homeland Security & Materials Management Division in ORD鈥檚 Center for Environmental Solutions and Emergency Response. In addition, Shawn is the National Program Director for EPA鈥檚 Homeland Security Research Program. Shawn has over 19 years of experience at EPA, including 16 years leading research to support EPA鈥檚 Homeland Security mission. He has initiated and led several large-scale interagency projects that have made significant advances in Homeland Security and served as models of partnership. His research focuses on biological and chemical agent-related decontamination.

Dr. Steve Stice is a University of Georgia, DW Brooks Distinguished Professor and Director of the Regenerative Bioscience Center, who holds a Georgia Research Alliance Eminent Scholar endowed chair, and is CSO of ArunA Biomedical Inc. He has over 30 years of research and development experience in biotechnology and is a co-founder of several biotech start-ups, including ArunA Biomedical; the first company to commercialize a product derived from human pluripotent stem cells, and cell development used to facilitate approval of Pfizer’s current cognitive enhancing pharmaceuticals.
Prior to joining UGA, Stice was the co-founder and served as both CSO and CEO of Advanced Cell Technology, the first USA Company to advance to human clinical trials using human pluripotent stem cells. Additionally, he co-founded startups; Prolinia and Cytogenesis which later merged with what is now, ViaCyte.
Outside of his academic professorship and business role, Stice co-directs The Regenerative Engineering and Medicine research center, or REM, a joint collaboration between Emory University, Georgia Institute of Technology and UGA, and is also a group leader of EBICS: Emergent Behaviors of Integrated Cellular Systems, a National Science Foundation Science and Technology Center founded by the Massachusetts Institute of Technology. As an invited member, he sits on the Scientific Advisory Board for the Food and Drug Administration (FDA), and is serving on the Governing Committee of the first institute funded by the U.S. Department of Commerce (DOC); National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), the eleventh institute in the Manufacturing USA government network.
Stice is a world-renown expert in the field of pluripotent stem cell biology. In 2001, he directed work on derivation of three human pluripotent stem cell lines which were approved for federal funding by the NIH and President Bush. One of several noteworthy achievements for Stice, was producing the first cloned rabbit in 1987 and the first cloned transgenic calves in 1998 (George and Charlie). In 1997 his group produced the first genetically modified embryonic stem cell derived pigs and cattle. Notably, the Stice lab was one of only five NIH sponsored sites for training NIH investigators on the propagation, differentiation and use of hESC over a six year period.
Currently, the Stice lab is developing novel therapies and new technologies for drug screening and neurodegenerative disease, which could change the lives of those suffering with Parkinson’s, Stroke injury, and Alzheimer’s. This research has led to publications in Science and Nature journals, national news coverage (CBS, NBC, ABC and CNN) and the first US patents on cloning animals and cattle stem cells which was featured in the Wall Street Journal. Most recently, Stice was elected to NAI Fellow status, the highest professional distinction accorded solely to academic inventors. Georgia Bio also honored Stice that same year with the 2017 Georgia Bio Industry Growth Award.

HRH Princess Dr. Al Saud’s distinguished career includes roles at the King Abdulaziz City for Science & Technology (KACST), both as Director of the Saudi National Center for Genomics Technology, and as Director of the Saudi National Pre-Marital Screening Program. She also served as a scientist at the King Faisal Specialized Hospital and Research Center, where she carried out a range of research projects focusing on population genetics.
HRH Princess Dr. Al Saud has served as a member of the National Biotech Strategy Advisory Committee at the Strategic Management Office, and as a member of the National Nutrition Committee at the Saudi Food & Drug Authority, as well as being a past and present member of a number of other notable national and international committees. These include serving as a member of the Project Oversight Executive team for the Saudi Genome Project 2.0 at KACST; the S20 Future of Health Taskforce at the G20 Summit; and a committee member for the Princess Noura Award for Women’s Excellence.
HRH Princess Dr. Al Saud holds a PhD in Genomics of Common Diseases from Imperial College London and a Master’s degree in Genetics and Toxicology from McGill University, as well as a Bachelor’s degree in Clinical Nutrition from King Saud University, Riyadh.

Zachary Turpin joined the English Department at University of Idaho in 2017. His research focuses on nineteenth-century periodical culture, archival research methods, digital humanities, and the history of epistemology and the sciences. Prior to joining U of I, he rediscovered two book-length works by the poet Walt Whitman: a novella (Life and Adventures of Jack Engle, 1852) and an urban men’s wellness manifesto (Manly Health and Training, 1858). Besides hunting for further possible Whitman publications, Turpin has worked with a number of collaborators to uncover unaccounted-for periodical works by American authors of the nineteenth and twentieth centuries, including Rebecca Harding Davis, Emma Lazarus, Mark Twain, Ambrose Bierce, Charles W. Chesnutt, Paul Laurence Dunbar, Anne Sexton, and Cormac McCarthy.
In 2017, he became a Kluge Fellow at the Library of Congress (Washington, DC), and in 2020 he was awarded a short-term Peterson Fellowship by the American Antiquarian Society (Worcester, MA). His teaching experience includes courses on American literature pre-1865, archival research methods, Great American Novels of the nineteenth century, Walt Whitman, Emily Dickinson, Herman Melville, nineteenth-century women’s literature, American Transcendentalism, and academic and professional writing.